Oxidative stress in blood in Alzheimer's disease and mild cognitive impairment: A meta-analysis

M. Schrag, C. Mueller, M. Zabel, A. Crofton, W. M. Kirsch, O. Ghribi, R. Squitti, G. Perry

Research output: Contribution to journalArticle

152 Citations (Scopus)

Abstract

Abnormal oxidative stress is an established feature of Alzheimer's disease, but clinical trials aiming to reduce oxidative stress have not yet proven an effective therapy for dementia patients. The purpose of this review is to systematically analyze available data describing markers of oxidative stress and antioxidants in blood from subjects with Alzheimer's disease or those with mild cognitive impairment to highlight potential interactions between peripheral redox changes and central nervous system pathology and contribute to the design of future clinical study. PubMed, SCOPUS and Web of Science were systematically queried to collect studies which have evaluated markers of oxidative stress, levels of antioxidants, copper, transferrin and ceruloplasmin levels in blood from subjects with Alzheimer's disease and matched controls. After application of quality measures, results were aggregated in a random effects analysis. We found that markers of lipid peroxidation are elevated in blood in Alzheimer's disease and in mild cognitive impairment, copper metabolism is dysregulated and total antioxidant capacity is decreased. While surprisingly none of the major antioxidative enzymes are significantly decreased, non-enzymatic antioxidants in blood (particularly uric acid, vitamins A, E and C, α- and β-carotene) are significantly decreased. There is significant oxidative damage in peripheral blood early in the process of neurodegeneration. We propose that clinical studies assessing cognitive outcomes after antioxidant therapy tailor interventions to individual patients' deficiencies and confirm an improvement in an appropriate serological marker of oxidative stress. This strategy may be most effectively applied in a clinical trial of primary prevention.

Original languageEnglish (US)
Pages (from-to)100-110
Number of pages11
JournalNeurobiology of Disease
Volume59
DOIs
StatePublished - Nov 1 2013

Fingerprint

Meta-Analysis
Alzheimer Disease
Oxidative Stress
Antioxidants
Copper
Clinical Trials
Ceruloplasmin
Carotenoids
Primary Prevention
Transferrin
Uric Acid
Vitamin A
Vitamin E
PubMed
Lipid Peroxidation
Ascorbic Acid
Oxidation-Reduction
Dementia
Central Nervous System
Cognitive Dysfunction

Keywords

  • Alzheimer's disease
  • Ceruloplasmin oxidase
  • Cognitive aging
  • Copper
  • Glutathione
  • Lipid peroxidation
  • Oxidative stress
  • Singlet oxygen

ASJC Scopus subject areas

  • Neurology

Cite this

Oxidative stress in blood in Alzheimer's disease and mild cognitive impairment : A meta-analysis. / Schrag, M.; Mueller, C.; Zabel, M.; Crofton, A.; Kirsch, W. M.; Ghribi, O.; Squitti, R.; Perry, G.

In: Neurobiology of Disease, Vol. 59, 01.11.2013, p. 100-110.

Research output: Contribution to journalArticle

Schrag, M. ; Mueller, C. ; Zabel, M. ; Crofton, A. ; Kirsch, W. M. ; Ghribi, O. ; Squitti, R. ; Perry, G. / Oxidative stress in blood in Alzheimer's disease and mild cognitive impairment : A meta-analysis. In: Neurobiology of Disease. 2013 ; Vol. 59. pp. 100-110.
@article{93d87a02792e4b30b9161028565da597,
title = "Oxidative stress in blood in Alzheimer's disease and mild cognitive impairment: A meta-analysis",
abstract = "Abnormal oxidative stress is an established feature of Alzheimer's disease, but clinical trials aiming to reduce oxidative stress have not yet proven an effective therapy for dementia patients. The purpose of this review is to systematically analyze available data describing markers of oxidative stress and antioxidants in blood from subjects with Alzheimer's disease or those with mild cognitive impairment to highlight potential interactions between peripheral redox changes and central nervous system pathology and contribute to the design of future clinical study. PubMed, SCOPUS and Web of Science were systematically queried to collect studies which have evaluated markers of oxidative stress, levels of antioxidants, copper, transferrin and ceruloplasmin levels in blood from subjects with Alzheimer's disease and matched controls. After application of quality measures, results were aggregated in a random effects analysis. We found that markers of lipid peroxidation are elevated in blood in Alzheimer's disease and in mild cognitive impairment, copper metabolism is dysregulated and total antioxidant capacity is decreased. While surprisingly none of the major antioxidative enzymes are significantly decreased, non-enzymatic antioxidants in blood (particularly uric acid, vitamins A, E and C, α- and β-carotene) are significantly decreased. There is significant oxidative damage in peripheral blood early in the process of neurodegeneration. We propose that clinical studies assessing cognitive outcomes after antioxidant therapy tailor interventions to individual patients' deficiencies and confirm an improvement in an appropriate serological marker of oxidative stress. This strategy may be most effectively applied in a clinical trial of primary prevention.",
keywords = "Alzheimer's disease, Ceruloplasmin oxidase, Cognitive aging, Copper, Glutathione, Lipid peroxidation, Oxidative stress, Singlet oxygen",
author = "M. Schrag and C. Mueller and M. Zabel and A. Crofton and Kirsch, {W. M.} and O. Ghribi and R. Squitti and G. Perry",
year = "2013",
month = "11",
day = "1",
doi = "10.1016/j.nbd.2013.07.005",
language = "English (US)",
volume = "59",
pages = "100--110",
journal = "Neurobiology of Disease",
issn = "0969-9961",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Oxidative stress in blood in Alzheimer's disease and mild cognitive impairment

T2 - A meta-analysis

AU - Schrag, M.

AU - Mueller, C.

AU - Zabel, M.

AU - Crofton, A.

AU - Kirsch, W. M.

AU - Ghribi, O.

AU - Squitti, R.

AU - Perry, G.

PY - 2013/11/1

Y1 - 2013/11/1

N2 - Abnormal oxidative stress is an established feature of Alzheimer's disease, but clinical trials aiming to reduce oxidative stress have not yet proven an effective therapy for dementia patients. The purpose of this review is to systematically analyze available data describing markers of oxidative stress and antioxidants in blood from subjects with Alzheimer's disease or those with mild cognitive impairment to highlight potential interactions between peripheral redox changes and central nervous system pathology and contribute to the design of future clinical study. PubMed, SCOPUS and Web of Science were systematically queried to collect studies which have evaluated markers of oxidative stress, levels of antioxidants, copper, transferrin and ceruloplasmin levels in blood from subjects with Alzheimer's disease and matched controls. After application of quality measures, results were aggregated in a random effects analysis. We found that markers of lipid peroxidation are elevated in blood in Alzheimer's disease and in mild cognitive impairment, copper metabolism is dysregulated and total antioxidant capacity is decreased. While surprisingly none of the major antioxidative enzymes are significantly decreased, non-enzymatic antioxidants in blood (particularly uric acid, vitamins A, E and C, α- and β-carotene) are significantly decreased. There is significant oxidative damage in peripheral blood early in the process of neurodegeneration. We propose that clinical studies assessing cognitive outcomes after antioxidant therapy tailor interventions to individual patients' deficiencies and confirm an improvement in an appropriate serological marker of oxidative stress. This strategy may be most effectively applied in a clinical trial of primary prevention.

AB - Abnormal oxidative stress is an established feature of Alzheimer's disease, but clinical trials aiming to reduce oxidative stress have not yet proven an effective therapy for dementia patients. The purpose of this review is to systematically analyze available data describing markers of oxidative stress and antioxidants in blood from subjects with Alzheimer's disease or those with mild cognitive impairment to highlight potential interactions between peripheral redox changes and central nervous system pathology and contribute to the design of future clinical study. PubMed, SCOPUS and Web of Science were systematically queried to collect studies which have evaluated markers of oxidative stress, levels of antioxidants, copper, transferrin and ceruloplasmin levels in blood from subjects with Alzheimer's disease and matched controls. After application of quality measures, results were aggregated in a random effects analysis. We found that markers of lipid peroxidation are elevated in blood in Alzheimer's disease and in mild cognitive impairment, copper metabolism is dysregulated and total antioxidant capacity is decreased. While surprisingly none of the major antioxidative enzymes are significantly decreased, non-enzymatic antioxidants in blood (particularly uric acid, vitamins A, E and C, α- and β-carotene) are significantly decreased. There is significant oxidative damage in peripheral blood early in the process of neurodegeneration. We propose that clinical studies assessing cognitive outcomes after antioxidant therapy tailor interventions to individual patients' deficiencies and confirm an improvement in an appropriate serological marker of oxidative stress. This strategy may be most effectively applied in a clinical trial of primary prevention.

KW - Alzheimer's disease

KW - Ceruloplasmin oxidase

KW - Cognitive aging

KW - Copper

KW - Glutathione

KW - Lipid peroxidation

KW - Oxidative stress

KW - Singlet oxygen

UR - http://www.scopus.com/inward/record.url?scp=84881630187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881630187&partnerID=8YFLogxK

U2 - 10.1016/j.nbd.2013.07.005

DO - 10.1016/j.nbd.2013.07.005

M3 - Article

C2 - 23867235

AN - SCOPUS:84881630187

VL - 59

SP - 100

EP - 110

JO - Neurobiology of Disease

JF - Neurobiology of Disease

SN - 0969-9961

ER -